RU2019110898A3 - - Google Patents

Download PDF

Info

Publication number
RU2019110898A3
RU2019110898A3 RU2019110898A RU2019110898A RU2019110898A3 RU 2019110898 A3 RU2019110898 A3 RU 2019110898A3 RU 2019110898 A RU2019110898 A RU 2019110898A RU 2019110898 A RU2019110898 A RU 2019110898A RU 2019110898 A3 RU2019110898 A3 RU 2019110898A3
Authority
RU
Russia
Application number
RU2019110898A
Other languages
Russian (ru)
Other versions
RU2741228C2 (en
RU2019110898A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019110898A3 publication Critical patent/RU2019110898A3/ru
Publication of RU2019110898A publication Critical patent/RU2019110898A/en
Application granted granted Critical
Publication of RU2741228C2 publication Critical patent/RU2741228C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019110898A 2016-11-14 2017-09-21 Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist RU2741228C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421677P 2016-11-14 2016-11-14
US62/421,677 2016-11-14
PCT/RU2017/000688 WO2018088933A1 (en) 2016-11-14 2017-09-21 Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist

Publications (3)

Publication Number Publication Date
RU2019110898A3 true RU2019110898A3 (en) 2020-12-14
RU2019110898A RU2019110898A (en) 2020-12-14
RU2741228C2 RU2741228C2 (en) 2021-01-22

Family

ID=62110006

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019110898A RU2741228C2 (en) 2016-11-14 2017-09-21 Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist

Country Status (2)

Country Link
RU (1) RU2741228C2 (en)
WO (1) WO2018088933A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223698A1 (en) * 2019-05-02 2020-11-05 Stimit Corporation Cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
RU2238776C1 (en) * 2003-02-25 2004-10-27 Челябинская государственная медицинская академия Method for applying heat-producing radiation therapy of prostate tumors
AU2005325715B2 (en) * 2004-12-16 2011-10-06 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
AR074439A1 (en) * 2008-12-02 2011-01-19 Pf Medicament ANTI-CMET ANTIBODY (C-MET RECEIVER)
JP5796014B2 (en) * 2009-10-06 2015-10-21 パナセラ ラブス， インコーポレイテッド Use of toll-like receptors and toll-like receptor agonists to treat cancer
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation

Also Published As

Publication number Publication date
RU2741228C2 (en) 2021-01-22
RU2019110898A (en) 2020-12-14
WO2018088933A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
BR122021017409A2 (en)
JP1602488S (en)
RU2017121845A3 (en)
BR112019009265A2 (en)
JP1569395S (en)
JP1583678S (en)
IL267385A (en)
JP1570575S (en)
JP1570316S (en)
JP1560428S (en)
BR102016014616A2 (en)
CN303538171S (en)
CN303542739S (en)
CN303539371S (en)
CN303539471S (en)
CN303539854S (en)
CN303540702S (en)
CN303540805S (en)
CN303541245S (en)
CN303541432S (en)
CN303541474S (en)
CN303541522S (en)
CN303541635S (en)
CN303541676S (en)
CN303541743S (en)